| Primary |
| Glioblastoma Multiforme |
26.4% |
| Glioblastoma |
16.0% |
| Prophylaxis |
9.8% |
| Product Used For Unknown Indication |
6.9% |
| Metastatic Malignant Melanoma |
6.3% |
| Ovarian Cancer |
5.4% |
| Drug Use For Unknown Indication |
5.1% |
| Acute Myeloid Leukaemia |
4.5% |
| Anaplastic Astrocytoma |
2.8% |
| Glioma |
2.7% |
| Medulloblastoma |
1.9% |
| Malignant Melanoma |
1.9% |
| Antifungal Prophylaxis |
1.8% |
| Malignant Glioma |
1.8% |
| Neoplasm |
1.8% |
| Pain |
1.1% |
| Brain Neoplasm Malignant |
1.1% |
| Brain Neoplasm |
0.9% |
| Nausea |
0.9% |
| Routine Health Maintenance |
0.8% |
|
| Thrombocytopenia |
14.9% |
| White Blood Cell Count Decreased |
14.9% |
| Vomiting |
14.1% |
| Platelet Count Decreased |
8.0% |
| Pulmonary Embolism |
5.8% |
| Pyrexia |
5.3% |
| Pneumonia |
5.2% |
| Urinary Tract Infection |
4.4% |
| Pancytopenia |
3.9% |
| Weight Decreased |
2.9% |
| Lymphopenia |
2.5% |
| Sepsis |
2.5% |
| White Blood Cell Count Increased |
2.4% |
| Febrile Neutropenia |
2.3% |
| Lymphocyte Count Decreased |
2.2% |
| Disease Progression |
1.9% |
| Convulsion |
1.8% |
| Somnolence |
1.8% |
| Deep Vein Thrombosis |
1.6% |
| Nausea |
1.5% |
|
| Secondary |
| Prophylaxis |
31.1% |
| Glioblastoma Multiforme |
18.1% |
| Glioblastoma |
10.6% |
| Anaplastic Astrocytoma |
8.2% |
| Drug Use For Unknown Indication |
7.9% |
| Product Used For Unknown Indication |
6.9% |
| Antifungal Prophylaxis |
4.9% |
| Metastatic Malignant Melanoma |
1.4% |
| Brain Stem Glioma |
1.4% |
| Medulloblastoma |
1.4% |
| Brain Neoplasm Malignant |
1.2% |
| Urinary Tract Infection |
1.0% |
| Glioma |
0.8% |
| Neoplasm |
0.8% |
| Central Nervous System Lymphoma |
0.8% |
| Epilepsy |
0.8% |
| Diabetes Mellitus |
0.7% |
| Gliosarcoma |
0.7% |
| Hypothyroidism |
0.7% |
| Constipation |
0.7% |
|
| White Blood Cell Count Decreased |
34.9% |
| Thrombocytopenia |
7.9% |
| Vomiting |
6.5% |
| White Blood Cell Count Increased |
4.4% |
| Radiation Necrosis |
4.1% |
| Pulmonary Embolism |
4.0% |
| Pyrexia |
4.0% |
| Urinary Tract Infection |
3.4% |
| Convulsion |
3.1% |
| Xeroderma |
3.1% |
| Neutropenia |
3.0% |
| Nausea |
2.8% |
| Protein Total Decreased |
2.8% |
| Purpura |
2.8% |
| Lymphocyte Count Decreased |
2.4% |
| Upper Respiratory Tract Inflammation |
2.3% |
| Weight Decreased |
2.3% |
| Death |
2.2% |
| Tumour Haemorrhage |
2.0% |
| Overdose |
1.9% |
|
| Concomitant |
| Glioblastoma Multiforme |
19.8% |
| Glioblastoma |
14.4% |
| Drug Use For Unknown Indication |
13.5% |
| Product Used For Unknown Indication |
11.4% |
| Metastatic Malignant Melanoma |
6.8% |
| Rhabdomyosarcoma |
4.6% |
| Sarcoma |
3.9% |
| Convulsion |
3.6% |
| Glioma |
2.6% |
| Neuroblastoma |
2.6% |
| Hypertension |
2.1% |
| Sarcoma Metastatic |
2.1% |
| Premedication |
1.8% |
| Anaplastic Astrocytoma |
1.6% |
| Colorectal Cancer |
1.6% |
| Oligodendroglioma |
1.6% |
| Schizophrenia |
1.6% |
| Brain Neoplasm |
1.5% |
| Brain Oedema |
1.5% |
| Complex Partial Seizures |
1.4% |
|
| Malignant Glioma |
9.4% |
| Epilepsy |
8.0% |
| Pulmonary Embolism |
8.0% |
| Thrombocytopenia |
8.0% |
| Optic Neuropathy |
6.5% |
| Vomiting |
6.5% |
| Angina Unstable |
5.8% |
| Pneumonia |
5.1% |
| Tubulointerstitial Nephritis |
5.1% |
| Convulsion |
4.3% |
| Neoplasm Malignant |
4.3% |
| Cerebral Haemorrhage |
3.6% |
| Death |
3.6% |
| Disease Progression |
3.6% |
| Large Intestine Perforation |
3.6% |
| Drug Eruption |
2.9% |
| Loss Of Consciousness |
2.9% |
| Oral Candidiasis |
2.9% |
| Rash |
2.9% |
| Tumour Lysis Syndrome |
2.9% |
|
| Interacting |
| Glioblastoma Multiforme |
19.3% |
| Urinary Tract Infection |
15.1% |
| Coordination Abnormal |
10.1% |
| Hemiparesis |
10.1% |
| Oligodendroglioma |
10.1% |
| Product Used For Unknown Indication |
10.1% |
| Drug Use For Unknown Indication |
8.4% |
| Status Epilepticus |
4.2% |
| Glioblastoma |
3.4% |
| Astrocytoma |
1.7% |
| Convulsion |
1.7% |
| Deep Vein Thrombosis |
1.7% |
| Mixed Oligo-astrocytoma |
1.7% |
| Prophylaxis Of Nausea And Vomiting |
1.7% |
| Hypercholesterolaemia |
0.8% |
|
| Thrombocytopenia |
45.0% |
| Ophthalmoplegia |
15.0% |
| Epilepsy |
10.0% |
| Liver Function Test Abnormal |
10.0% |
| Paralysis |
10.0% |
| Hepatic Failure |
5.0% |
| White Blood Cell Count Decreased |
5.0% |
|
